NIDDK Central Repository - Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

An official website of the United States government

This repository is under review for potential modification in compliance with Administration directives.

NIDDK Central Repository

Publication Information

DOI

10.1053/j.gastro.2006.06.008

PubMed ID

16890601

Public Release Type

Journal

Publication Year

2006

Affiliation

Division of Gastroenterology, The University of Michigan, Ann Arbor, Michigan 48109-0362, USA. omsairam@umich.edu

Authors

Afdhal N, Belle SH, Brown RS, Conjeevaram HS, Fried MW, Hoofnagle JH, Howell CD, Jeffers LJ, Kleiner DE, Terrault NA, Virahep-C Study Group, Wiley-Lucas TE

Studies

Virahep-C

Citation

Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, Brown RS, Belle SH, Hoofnagle JH, Kleiner DE, Howell CD, Virahep-C Study Group. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006 Aug;131(2):470-7.

Abstract

Compared with Caucasian Americans (CA), African Americans (AA) with chronic hepatitis C are less likely to respond to interferon-based antiviral therapy.